ALEMBIC THERAP
PharmaALEMBIC THERAP is a pharmaceutical company focused on Infectious Disease, Dermatology, Cardiovascular. Key products include NUVESSA.
ALEMBIC THERAP's Key Drugs
ALEMBIC THERAP's core commercial portfolio centers on NUVESSA, PIVYA, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.
ALEMBIC THERAP's Recent FDA Approvals
New NDA/BLA approvals for ALEMBIC THERAP over the last two years — novel drugs only, excluding generics and label supplements.
ALEMBIC THERAP's Therapeutic Areas
ALEMBIC THERAP's approved drugs and pipeline span 4 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALEMBIC THERAP's Top Competitors
ALEMBIC THERAP's closest competitors by therapeutic-area and drug-target overlap include B BRAUN, BAUSCH AND LOMB INC, and FOUGERA PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALEMBIC THERAP Pipeline Snapshot
Active clinical trials for ALEMBIC THERAP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NUVESSA leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling